1. Home
  2. VOYA vs CELC Comparison

VOYA vs CELC Comparison

Compare VOYA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Financial Inc.

VOYA

Voya Financial Inc.

HOLD

Current Price

$97.52

Market Cap

8.3B

Sector

Finance

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$108.64

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOYA
CELC
Founded
1975
2011
Country
United States
United States
Employees
11000
N/A
Industry
Life Insurance
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
7.0B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
VOYA
CELC
Price
$97.52
$108.64
Analyst Decision
Buy
Strong Buy
Analyst Count
10
9
Target Price
$84.90
$112.56
AVG Volume (30 Days)
1.2M
1.1M
Earning Date
05-05-2026
05-13-2026
Dividend Yield
2.31%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.13
N/A
Revenue Next Year
$3.93
$720.19
P/E Ratio
$12.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$64.50
$13.39
52 Week High
$98.72
$151.02

Technical Indicators

Market Signals
Indicator
VOYA
CELC
Relative Strength Index (RSI) 77.27 53.91
Support Level $72.93 $99.38
Resistance Level N/A $117.61
Average True Range (ATR) 2.38 5.75
MACD 0.26 2.70
Stochastic Oscillator 87.07 71.66

Price Performance

Historical Comparison
VOYA
CELC

About VOYA Voya Financial Inc.

Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Retirement, Investment Management and Employee Benefits.The majority revenue is from Retirement segment.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: